|
An Overview on HPV in Head and Neck Squamous Cell Carcinoma
|
|
| Author:
|
MS. LAEEQ, DR.SHALINI GUPTA, DR.MOHATSIM LOHANI
|
| Abstract:
|
Head and Neck Squamous Cell Carcinoma malignant disease is associated with human papillomavirus (HPV) 16 infection. Human papillomavirus (HPV) is a virus often infecting humans. It is often present on skin or mucous membranes. This diverse DNA virus is often linked to many various benign and malignant neoplastic lesions. The biology of HPV-positive oropharyngeal cancer is distinct with P53 degradation, retinoblastoma RB pathway inactivation, and P16 upregulation. By contrast, tobacco-related oropharyngeal cancer is characterised by TP53 mutation and downregulation of CDKN2A (encoding P16). The best method to detect virus in tumour is controversial, and both in-situ hybridisation and PCR are commonly used; P16 immunohistochemistry could serve as a potential surrogate marker. HPV-positive oropharyngeal cancer seems to be more responsive to chemotherapy and radiation than HPV-negative disease. Many patients with oropharyngeal cancer have no common risk factors, and recent epidemiologic and molecular studies have identified high-risk types of human papillomavirus (HPV), especially HPV- 16, as the potential etiologic agents. The widespread use of prophylactic HPV vaccines combined with vigilant Pap smear and HPV-DNA testing has the potential to eliminate many of these cancers. In the future, antiviral pharmaceutical approaches and therapeutic vaccination may allow effective, nontoxic therapy.
|
| Keyword:
|
HPV, OSCC, Vaccines, Targeted therapies, Immunotherapy,Tumour.
|
| EOI:
|
-
|
| DOI:
|
-
|
| Download:
|
Request For Article
|
|
|